IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

SR One Capital Management, LP

Q2 2025 Holdings

Filed 2025-08-14 | 13 holdings | $461.4M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Arcellx, Inc.(ACLX)Common Stock03940C100$154.5M2,346,63033.5%
ARS Pharmaceuticals, Inc.(SPRY)Common Stock82835W108$70.0M4,012,90315.2%
Crispr Therapeutics AG(CRSP)Common SharesH17182108$51.0M1,048,95111.1%
Zenas BioPharma, Inc(ZBIO)Common Stock98937L105$47.6M4,911,53910.3%
Oric Pharmaceuticals, Inc.(ORIC)Common Stock68622P109$45.8M4,514,9299.9%
Mineralys Therapeutics Inc.(MLYS)Common Stock603170101$42.3M3,127,9339.2%
Design Therapeutics, Inc.(DSGN)Common Stock25056L103$22.0M6,526,4764.8%
Oculis Holding AG(OCS)Ordinary SharesH5870P102$6.3M322,5001.4%
Alumis Inc.(ALMS)Common Stock022307102$5.9M1,959,8961.3%
Nkarta, Inc.(NKTX)Common Stock65487U108$5.5M3,333,3331.2%
Oruka Therapeutics, Inc(ORKA)Common Stock687604108$4.8M430,3301.0%
Kala Bio, Inc.(KALA)Common Stock483119202$2.9M598,9400.6%
enGene Holdings Inc.(ENGN)Common Shares29286M105$2.7M747,7500.6%